logo

For the Inventor, By the Inventor

Kiel, Germany

Conaris Research Institute

Calculating rank
USPTO Granted Patents = 13

% Expired Patents = 7.7



Forward Citations = 50

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Dirk Seegert (10 out of 10 patents)

silverMedal Georg Wätzig (7 out of 7 patents)

bronzeMedal Stefan Rose-John (4 out of 12 patents)

4.  Nikolaus Rahaus (3 out of 3 patents)

5.  Georg Waetzig (2 out of 2 patents)

6.  Stefan Schreiber (2 out of 3 patents)

7.  Georg H Watzig (2 out of 2 patents)

8.  Alfred Chi Yeh Liang (1 out of 2 patents)

9.  Venkataramana Dingari (1 out of 2 patents)

10.  Bent Højgaard (1 out of 1 patent)

11.  Jørgen Wittendorff (1 out of 1 patent)

12.  Joachim Grötzinger (1 out of 3 patents)

13.  Jürgen Scheller (1 out of 2 patents)

14.  Stephanie Tenhumberg (1 out of 1 patent)

15.  Jessica Daecke (1 out of 1 patent)


13 patents:

1. 11622938 - Oral pharmaceutical compositions of nicotinamide (2023-04-11),
2. 10888555 - Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota (2021-01-12),
3. 10758552 - Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation (2020-09-01),
4. 10456389 - Extended release nicotinamide formulation (2019-10-29),
5. 10426765 - Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota (2019-10-01),
6. 9573989 - Sgp130/Fc dimers (2017-02-21),
7. 9034817 - sgp130/Fc dimers for treatment of inflammatory disease (2015-05-19),
8. 8895012 - sgp130/Fc dimers (2014-11-25),
9. 8501696 - Soluble GP130 muteins with improved binding activity (2013-08-06),
10. 8206948 - Optimized nucleotide sequences encoding sgp130 (2012-06-26),
11. 7851182 - Soluble GP130 molecule variants useful as a medicament (2010-12-14),
12. 7629147 - PEGylated soluble GP130-dimers useful as a medicament (2009-12-08),
13. 7534862 - PEGylated soluble gp130-dimers useful as a medicament (2009-05-19),
Company Overview
Conaris Research Institute, based in Kiel, Germany, specializes in advanced research and development in the fields of materials science and engineering. The organization focuses on innovative solutions that enhance performance and sustainability across various applications. With a commitment to fostering technological advancements, Conaris engages in collaborative projects that bridge academia and industry, aiming to drive progress in sectors such as energy, automotive, and manufacturing. Their expertise positions them as a key player in the European research landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

13 Patents

#9 in Kiel

#3,086 in Germany

#45,085 in the World

Kiel, DE
Kiel, Germany

Conaris Research Institute

Forward Citations = 50

15 inventors:

goldMedal Dirk Seegert (10 out of 10 patents)

silverMedal Georg Wätzig (7 out of 7 patents)

bronzeMedal Stefan Rose-John (4 out of 12 patents)

4.  Nikolaus Rahaus (3 out of 3 patents)

5.  Georg Waetzig (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Conaris Research Institute. Retrieved from https://idiyas.com/company/conaris-research-institute

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…